Provided by Tiger Trade Technology Pte. Ltd.

Cocrystal Pharma, Inc.

0.9699
+0.109712.75%
Post-market: 0.97990.0100+1.03%19:59 EST
Volume:109.25K
Turnover:102.76K
Market Cap:13.37M
PE:-1.04
High:0.9880
Open:0.8800
Low:0.8800
Close:0.8602
52wk High:2.67
52wk Low:0.8588
Shares:13.78M
Float Shares:9.35M
Volume Ratio:0.97
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9317
EPS(LYR):-1.7205
ROE:-94.94%
ROA:-45.77%
PB:1.74
PE(LYR):-0.56

Loading ...

Cocrystal Pharma Grants Stock Options to Directors and Executives Under New Equity Plan

Reuters
·
Jan 16

Director and 10% Owner Phillip Frost Reports Acquisition of Cocrystal Pharma Common Shares

Reuters
·
Jan 01

BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine

Reuters
·
Dec 18, 2025

Cocrystal Pharma Receives IRB Approval for Phase 1b Norovirus Study

Reuters
·
Dec 18, 2025

Cocrystal Pharma Receives Irb Approval From Emory University School of Medicine for Phase 1B Human Challenge Study With Cdi-988 for Prevention and Treatment of Norovirus

THOMSON REUTERS
·
Dec 18, 2025

Cocrystal Pharma Inc - Subject Enrollment for Study Expected to Begin in Q1 2026

THOMSON REUTERS
·
Dec 18, 2025

Cocrystal Pharma Inc. unveils investor presentation highlighting advances in broad-spectrum antiviral drug development

Reuters
·
Dec 02, 2025

Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares

Reuters
·
Nov 26, 2025

Cocrystal Pharma Receives FDA Clearance and NIH Grant to Advance Norovirus and Influenza Programs

Reuters
·
Nov 14, 2025

Cocrystal Pharma Q3 loss narrows

Reuters
·
Nov 14, 2025

BRIEF-Cocrystal Pharma Q3 Net Income USD -2.049 Million

Reuters
·
Nov 14, 2025

Cocrystal Pharma Q3 Basic EPS USD -0.19

THOMSON REUTERS
·
Nov 14, 2025

Cocrystal Pharma Inc - Phase 1B Norovirus Study for Cdi-988 Expected in Q1 2026

THOMSON REUTERS
·
Nov 14, 2025

Cocrystal Pharma Q3 Operating Expenses USD 2.089 Million

THOMSON REUTERS
·
Nov 14, 2025

Cocrystal Pharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Oct 30, 2025

Noble Financial Remains a Buy on Cocrystal Pharma (COCP)

TIPRANKS
·
Oct 23, 2025

Cocrystal Pharma Inc publishes investor presentation on advancing broad spectrum antiviral drug candidates for influenza norovirus and coronavirus

Reuters
·
Oct 10, 2025

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

TIPRANKS
·
Sep 20, 2025

Cocrystal Pharma Inc. Completes $13 Million Direct Offering with Warrants for Additional Funding

Reuters
·
Sep 16, 2025